Effect of vitamin D analogues on acute cardiorenal syndrome: A laboratory rat model

Israel Medical Association Journal

Volumn 15, Issue 11, 2013, Pages 693-697

  Havakuk, Ofer ^a   Entin Meer, Michal ^a,b   Ben Shoshan, Jeremy ^a,b   Goryainov, Pavel ^a   Maysel Auslender, Sofia ^a   Joffe, Erel ^a   Keren, Gad ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cardiac function; Cardiorenal syndrome (CRS); Myocardial fibrosis; T regulatory cells (Treg); Vitamin D analogues

Indexed keywords

CREATININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PARICALCITOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CARDIORENAL SYNDROME; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEART FUNCTION; HEART FUNCTION TEST; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART SIZE; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LAPAROTOMY; MALE; NONHUMAN; RAT; REGULATORY T LYMPHOCYTE; THORACOTOMY; TRANSTHORACIC ECHOCARDIOGRAPHY; UNINEPHRECTOMY; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84888328987     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-119.
2. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16-23.
3. Culleton BF, Larson MG, Wilson P W, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufciency. Kidney Int 1999; 56: 2214-2219.
4. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufciency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 6296
5. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17 (7): 2034-2047.
6. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210.
7. Hillege HL, Nitsch D, Pfefer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678.
8. Hillege HL, van Gilst WH, van Veldhuisen DJ, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24: 412-4120.
9. Berton G, Cordiano R, Palmieri R, Cucchini F, De Toni R, Palatini P. Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality. Eur Heart J 2001; 22: 1466-1475.
10. Mento PF, Maita ME, Murphy WR, Holt WF, Wilkes BM. Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction. J Cardiovasc Pharmacol 1993; 21: 791-796.
11. Ben-Shoshan J, Michal Entin-Meer M, Guzner-Gur H, Keren G. Te cardiorenal syndrome: a mutual approach to concomitant cardiac and renal failure. IMAJ 2012: 14: 570-576.
12. Mento PF, Maita ME, Wilkes BM. Renal hemodynamics in rats with myocardial infarction: selective antagonism of angiotensin receptor subtypes. Am J Physiol 1996; 271: H2306-2312.
13. Gschwend S, Buikema H, Henning RH, Pinto YM, de Zeeuw D, van Gilst WH. Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure. Eur J Heart Fail 2003; 5: 147-154.
14. Gschwend S, Buikema H, Navis G, Henning RH, de Zeeuw D, van Dokkum R P. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. J Am Soc Nephrol 2002; 13: 2909-215.
15. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
16. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
17. Kalantar-Zadeh K, Kuwaen, Regidor D, et al. Survival predictability time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
18. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
19. Simpson RU, Tomas GA, Arnold AJ. Identification of 1,25 dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 1985; 260: 8882-8891.
20. Cheng S, Glenn DJ, Grigbsby L, et al. Expression of the vitamin D receptor is increased in the hypertropic heart. Hypertension 2008; 52: 1106-1112.
21. Mizobuchi M, Nakamura H, Tokumoto M, et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010; 121 (1-2): 188-192.
22. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+) CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006; 27 (21): 2530-2537.
23. Bair TL, May HT, Horne BD, et al. Vitamin D deficiency is strongly associated with incident death and cardiovascular disease in a general healthcare population. Circulation 2009; 120: S455.
24. Wang TJ, Pencina MJ, Booth SL, Jacques PF, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117 (4): 503-511.
25. Oh J, Weng S, Felton SK, et al. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009; 120 (8): 687-698.